Moderna & Merck Announce mRNA-4157/V940, an Investigational
Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (Pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial in Stage III/IVMelanoma; Resul…https://t.co/ZzI3UxXxey https://t.co/ybYnlUqlW5
Moderna & Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (Pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial in Stage III/IVMelanoma; Resul…https://t.co/3pt5a4gjyI https://t.co/ybYnlUqlW5
#Aging Associated with Systemic Length-Associated #Transcriptome Imbalance; Aging Is Accompanied by Shift in Gene Activity Toward Shorter Gene Transcripts, Which Are Associated with #AcceleratedAging; Longer Gene Transcripts Associated with Longer #Lifesp…https://t.co/Cl9p23tx8T